Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P04626 (erbB-2)
 5,251 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We examined the relationship between c-erbB-2, ras, and c-myc expression with various clinicopathologic variables and silver-stained nuclear organizer region (Ag-NOR) counts in 74 patients with breast cancer. c-erbB-2 expression correlated significantly with axillary (AX) metastases and Ag-NOR counts, whereas ras expression did not correlate with any clinicopathologic variables or the Ag-NOR counts. c-myc expression correlated significantly with the histologic type, but not with the other clinicopathologic variables or the Ag-NOR counts. Among the patients with positive c-erbB-2 expression, however, an increased incidence of AX metastases and Ag-NOR counts were observed in the group with positive c-mvc and/or ras expression. Nevertheless, of the three genes, only c-erbB-2 expression appeared to be an important prognostic factor in the univariate analysis, and in the multivariate analysis in which AX metastases were excluded from the Cox model. Therefore, it was concluded that of the three genes, c-erbB-2 expression has the strongest prognostic value in breast cancer.
 ...
PMID:C-erbb-2, ras p21, and C-myc expression in breast-carcinoma - prognostic value and correlation with clinicopathological and biologic variables. 2156 21

The study was based on the biopsy material collected in Eastern coastal region of South Africa with high incidence of primary hepatocellular carcinoma (HCC). Forty-one patients were between 9 and 25 years old of the total number of 474 cases of HCC available for examination. Liver biopsies were fixed in 10% of neutralised formalin, processed to paraffin blocks, cut and stained with hematoxylin and eosin, silver reticulin, Masson trichrome and Prussian blue stains. Representative biopsies of 21 patients younger than 25 years and 56 older than 35 years were in addition examined immunohistochemically with HBsAg antibody, endothelial marker (F VIII-related antigen) and for oncoproteins c-myc and c-erbB-2 using peroxidase-antiperoxidase method. Cirrhotic liver was evident in 41.5% of all patients and in 28% of younger than 25 years. Hemosiderosis of the liver of patients over 35 years was nearly twice as common as in younger than 25 years and showed the opposite relationship to the presence of HBsAg in liver tissue. Oncoprotein expression was also higher in tumor tissue of younger patients. These results indicate the etiological association of HCC with HBV infection, cirrhosis and possibly siderosis of the liver with HCC. Simultaneous expression of oncoproteins and HBsAg indicate the primary importance of viral infection in etiopathogenesis of HCC.
 ...
PMID:Hepatocellular carcinoma in young patients. 2159 36

We examined epidermal growth factor receptor (EGFR) and/or c-erbB-2 expression, clinicopathological variables, silver-stained nuclear organizer region (Ag-NOR) counts, and their prognostic values in 93 patients with operable breast carcinoma. There was no significant correlation between c-erbB-2 and EGFR expression. Increased Ag-NOR counts were significantly associated with positive c-erbB-2 expression, but not with positive EGFR expression. However, co-expression of both proteins was significantly correlated with axillary lymph node metastases. Significant differences in survival were found between groups of patients stratified by tumor size, histological grade, axillary lymph node metastases, c-erbB-2, and EGFR expression by univariate analysis. In addition, c-erbB-2 and EGFR expression in combination was strongly correlated with decreased survival. However, only axillary lymph node metastases and age appeared to be independent prognostic factors by multivariate analysis. We therefore conclude that the prognostic value of c-erbB-2 and EGFR expression is limited in breast carcinoma.
 ...
PMID:Expression of C-erbb-2 and epidermal growth-factor receptor in breast-carcinoma - prognostic value and correlation with clinicopathological and biological variables. 2160 5

The importance of anti-HER2 therapy has focused attention on the ability of clinical assays to correctly assign HER2 amplification status. In the present study, we evaluated HER2 mRNA expression using a new mRNA in situ detection technique called RNAscope in 211 cases of formalin-fixed, paraffin-embedded gastric carcinoma. In addition, we compared the results with the conventional methods of immunohistochemistry, fluorescence in situ hybridization, and dual-color silver in situ hybridization. RNA in situ hybridization (in situ hybridization) showed that 162 cases (76.8%) were score 0, 5 cases (2.4%) were score 1, 10 cases (4.7%) were score 2, 13 cases (6.2%) were score 3, and 21 cases (10.0%) were score 4. HER2 transcription levels were found to be significantly related to pT class, pN class, and tumor recurrence. mRNA expression was well correlated with protein overexpression and gene amplification; 20 cases out of 23 with DNA amplification showed a score of 4 in RNA in situ hybridization (P < .001). Three cases showed false negative and one case showed false positive results by in situ hybridization. More studies are needed to determine whether the in situ hybridization method can identify additional patients that may benefit from anti-HER2 therapy or exclude those who may be resistant to anti-HER2 therapy.
 ...
PMID:In situ analysis of HER2 mRNA in gastric carcinoma: comparison with fluorescence in situ hybridization, dual-color silver in situ hybridization, and immunohistochemistry. 2308 83

This study aimed at determining the incidence and clinical implications of HER2 status in primary colorectal cancer (CRC). HER2 status was investigated in two retrospective cohorts of 365 consecutive CRC patients (cohort 1) and 174 advanced CRC patients with synchronous or metachronous distant metastasis (cohort 2). HER2 status was determined by performing dual-color silver in-situ hybridization (SISH), mRNA in-situ hybridization (ISH), and immunohistochemistry (IHC). The incidence of HER2 protein overexpression (IHC 2+/3+) was approximately 6% (22 of 365 in cohort 1; 10 of 174 in cohort 2). HER2 gene amplification was observed in 5.8% of the patients from cohort 1 and 6.3% of the patients from cohort 2. HER2 gene amplification was more frequently observed in CRCs located in the rectum than in the right and left colon (P = 0.013 in cohort 1; P = 0.009 in cohort 2). HER2 status, determined by IHC, ISH, and dual-color SISH, was not significantly associated with aggressive CRC behaviour or patients' prognosis in both the cohorts. Of the combined cohort with a total of 539 cases, the concordance rate was 95.5% between dual-color SISH and IHC detection methods. On excluding equivocally immunostained cases (IHC 2+), the concordance rate was 97.7%. HER2 mRNA overtranscription, detected by ISH, significantly correlated with protein overexpression and gene amplification (P<0.001). HER2 gene amplification was identified in a minority of CRC patients with high concordance rates between dual-color SISH and IHC detection methods. Although HER2 status did not predict patients' prognosis, our findings may serve as a basis for future studies on patient selection for HER2 targeted therapy.
 ...
PMID:HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression. 2487 38


<< Previous 1 2